

## Research Article

# Partial Purification and Characterization of Bacteriocin-Like Inhibitory Substances Produced by *Streptomyces* sp. Isolated from the Gut of *Chanos chanos*

Muhammad A. Kurnianto,<sup>1,2</sup> Harsi D. Kusumaningrum ,<sup>3</sup> Hanifah N. Lioe,<sup>3</sup> and Ekowati Chasanah<sup>4</sup>

<sup>1</sup>Food Science Study Program, Graduate School, IPB University, Bogor, Indonesia

<sup>2</sup>Department of Food Technology, Faculty of Engineering, Universitas Pembangunan Nasional “Veteran” Jawa Timur, Surabaya, Indonesia

<sup>3</sup>Department of Food Science and Technology, Faculty of Agricultural Engineering and Technology, IPB University, Bogor, Indonesia

<sup>4</sup>Research and Development Center for Marine and Fisheries Product Processing and Biotechnology, Ministry of Marine and Fisheries, Jakarta, Indonesia

Correspondence should be addressed to Harsi D. Kusumaningrum; [h\\_kusumaningrum@apps.ipb.ac.id](mailto:h_kusumaningrum@apps.ipb.ac.id)

Received 6 July 2021; Revised 8 October 2021; Accepted 30 November 2021; Published 14 December 2021

Academic Editor: M. C D Vanetti

Copyright © 2021 Muhammad A. Kurnianto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Bacteriocin-like inhibitory substances (BLIS) have sparked great interest because of their promising use in food as natural antimicrobial agents. In this work, six *Streptomyces* isolates obtained from the gut of *Chanos chanos* demonstrated their ability to produce extracellular metabolites with inhibitory activity against *Salmonella enterica* serovar Typhimurium, *Escherichia coli*, *Listeria monocytogenes*, and *Staphylococcus aureus*. Exposure of the extracellular metabolites to proteolytic enzymes (i.e., proteinase-K, trypsin, and pepsin) revealed high sensitivity and confirmed their proteinaceous nature. The metabolites were stable at high temperatures (up to 100°C for 30 min) and a wide range of pH (pH 2.0–7.0). Fractionation of the crude BLIS by filtration yielded three fractions based on molecular weight: <3 kDa, 3–10 kDa, and >10 kDa. Analysis of the antibacterial activity of these fractions showed increased specific activity, especially in the fraction with a molecular weight (MW) of <3 kDa, relative to the crude sample. The fraction with MW <3 kDa had minimum inhibitory and bactericidal concentrations in ranges 0.04–0.62 mg·mL<sup>-1</sup> and 0.08–1.25 mg·mL<sup>-1</sup>, respectively. This fraction also showed better temperature and pH stability compared with crude BLIS. Brine shrimp toxicity assay revealed that this fraction has moderate toxicity with a 50% lethal concentration of 226.975 µg·mL<sup>-1</sup> (i.e., moderate toxicity) to *Artemia salina*. Identification of the peptide sequences of this fraction by liquid chromatography–tandem mass spectrometry yielded 130 proteins with retention times of 15.21–19.57 min. Eleven proteins with MWs of 1345.66–2908.35 Da and composed of less than 30 amino acid residues with high hydrophobicity (15.34–26.22 kcal·mol<sup>-1</sup>) appeared to be responsible for the antibacterial activity of the fraction. This study revealed the potential application of BLIS from *Streptomyces*, especially BLIS SCA-8, as antibacterial agents.

## 1. Introduction

Increasing consumer awareness of the adverse health effects of chemical preservative in food has resulted in heightened interest in fresh and minimally processed food [1–3]. However, this trend presents a massive challenge because minimally processed food is closely related to various diseases

caused by pathogenic bacteria [4, 5]. Hence, numerous explorations of potential natural preservatives, such as bacteriocins or bacteriocin-like inhibitory substances (BLIS), have been conducted in efforts to replace chemical preservatives to improve the shelf life and safety of food [6, 7].

Bacteriocins are short-chain protein or polypeptide compounds synthesized ribosomally by microorganisms that

could inhibit the growth of bacterial strains closely related to the bacteriocin-producing strains [7, 8]. The term BLIS describes a peptide or protein antimicrobial compound that is synthesized by ribosomes but not fully characterized by its amino acid sequence and biochemical properties [9]. Bacteriocins may be divided on the basis of their structure into three main classes: class I includes lantibiotics, class II includes small posttranslationally unmodified bacteriocins, and class III includes large antibacterial proteins (>10 kDa) and bacteriolysins [10]. Bacteriocins generally have a narrow antibacterial spectrum and are limited to closely related genera or species [7]. However, the growing demand for natural agents for food preservation (i.e., to replace chemical preservatives) or clinical applications renders the study and exploration of bacteriocins with broad spectrum antibacterial activity increasingly necessary [11, 12].

Most bacteriocins are produced by lactic acid bacteria, such as those belonging to *Lactococcus*, *Lactobacillus*, *Streptococcus*, and *Pediococcus* [7, 10]. Some bacteria from other genera, one of which is *Streptomyces*, are also capable of producing bacteriocins or BLIS with potential antibacterial activity and stability [13]. Several authors have examined the bacteriocins produced by *Streptomyces pluripotens* sp. nov. [14], *Streptomyces scopuliridis* sp. nov. [15], *Streptomyces griseus* (grisemycin) [16], and *Streptomyces bottropensis* (bottromycin A2) [17]. These studies show that *Streptomyces* bacteriocins have broad spectrum antibacterial activity against Gram-positive and negative bacteria and even resistant pathogenic bacteria, such as methicillin-resistant *Staphylococcus aureus* [14]. However, although the potential activity of some BLIS produced by *Streptomyces* has been reported, many other *Streptomyces* species producing these substances have not been described [13].

*Streptomyces* is a Gram-positive bacterium widely known to produce various bioactive compounds [18]. These bacteria are widely abundant in various ecosystems and can form associations with eukaryotic hosts, such as fish [19, 20]. This ability confers the bacterium with the physiological and genetic ability to adapt and express metabolites of varying bioactivity [21]. Several studies have discovered metabolites with potential bioactivity produced by *Streptomyces* associated with fish [20, 22, 23]. Kurnianto et al. [23, 24], for instance, identified a suspected peptide-containing antibacterial metabolite with broad spectrum antibacterial activity produced by *Streptomyces* associated with *Chanos chanos*.

The present study is aimed at analyzing the potential of six *Streptomyces* isolates from the gut of *C. chanos* to produce BLIS, at analyzing the stability and antibacterial activity characteristics of BLIS, and at identifying the active fraction of BLIS using liquid chromatography-tandem mass spectrometry (LC-MS/MS).

## 2. Materials and Methods

**2.1. Bacterial Strains and Culture Collection.** Six *Streptomyces* (i.e., *S. variabilis* SCA-5, *S. variabilis* SCA-11, *S. variabilis* AIA-10, *S. labedae* SCA-8, *S. globisporus* AIA-12, and *S. missionensis* AIA-17) were obtained from the gut of milkfish (*C. chanos*) [23, 24]. The strains were identified through their

morphological, physiological, biochemical, and molecular characteristics by 16S rRNA gene sequencing. The isolates were cultivated in ISP-2 medium (yeast extract, 4 g; malt extract, 10 g; dextrose broth, 4 g; bacteriological agar, 20 g; and distilled water, 1,000 mL) and incubated at 30°C. Target bacteria, including *Salmonella enterica* serovar Typhimurium ATCC 14028, *Escherichia coli* ATCC 25922, *Listeria monocytogenes* ATCC 35152, and *S. aureus* ATCC 25923, were grown on tryptic soy broth (Oxoid, UK) and incubated for 24 hours at 37°C.

**2.2. Production and Preliminary Screening of BLIS-Producing Bacteria.** The six *Streptomyces* isolates were inoculated on ISP-2 and incubated at 30°C during the optimum antibacterial production time (9–11 days) with agitation in a shaker incubator (New Brunswick, Germany) [24]. Bacterial cultures were centrifuged (Hermle, Germany) at  $7,000 \times g$  and 4°C for 15 min to separate the supernatant from the cell biomass. The supernatants were adjusted to pH 6.5–7.0 with  $1 \text{ mol} \cdot \text{L}^{-1}$  NaOH (Merck, Germany) and passed through a  $0.22 \mu\text{m}$  membrane filter (Sartorius, France) to obtain a neutralized cell-free supernatant (CFS). This CFS was analyzed for its inhibitory activity against two bacteria (i.e., *E. coli* ATCC 25922 and *S. aureus* ATCC 25922) via the microdilution method [25]. A total of  $100 \mu\text{L}$  of the tested bacterial suspension ( $1 \times 10^6 \text{ CFU} \cdot \text{mL}^{-1}$ ),  $80 \mu\text{L}$  of Mueller–Hinton broth medium (MHB) (Oxoid, UK), and  $20 \mu\text{L}$  of the CFS were added to each well of a microplate. Test bacteria grown on MHB medium without exposure to the CFS were used as controls. The microplate was incubated for 24 h at 37°C, and the absorbance of each well of the microplate was measured at 600 nm using an ELISA reader (Bio-Rad, US). The growth inhibitory activity of the test bacteria was calculated from the absorbance of samples with and without treatment (control). An absorbance value lower than the control indicates inhibition of the growth of the test bacteria. CFS samples showing potential activity were concentrated using a freeze dryer (Christ, Germany) to obtain crude BLIS.

**2.3. Confirmation of the Proteinaceous Nature of Crude BLIS.** The proteinaceous nature of crude BLIS was assessed by exposure of the six concentrated CFS samples to various enzymes, including proteinase-K (Geneaid, Taiwan), trypsin (Sigma-Aldrich, USA), and pepsin (Sigma-Aldrich), at a final concentration of  $10 \text{ mg} \cdot \text{mL}^{-1}$  and incubation for 2 h at 37°C. The samples were heated for 2 min to inactivate the enzyme, cooled to room temperature, and then subjected to antimicrobial activity testing [11] by using the agar well diffusion method.

**2.4. Partial Purification via Ultrafiltration Membranes.** The six crude BLIS samples were separated according to molecular weight by using 3 and 10 kDa ultracentrifuges (Amicon Ultra Centrifugal Unit, Regenerated Cellulose 3,000 and 10,000 MWCO, Merck Millipore Ltd., Germany) for 60 min at  $1,328.4 \times g$  and 4°C. This process separated the samples into three BLIS ultrafiltration fractions (BLIS-UF), i.e., <3 kDa, 3–10 kDa, and >10 kDa [26]. Each fraction was concentrated with a freeze dryer (Christ, Germany), adjusted

to a final volume of 80 mL with deionized water, and then subjected to bacterial inhibitory activity tests to assess their bioactivity.

**2.5. Quantification of Total Protein.** The total protein concentration of each sample was determined on the basis of the Bradford method (Bradford 1976), which refers to Jamaluddin et al. [27]. A total of 160  $\mu\text{L}$  of each sample was reacted with 40  $\mu\text{L}$  of Bradford reagent in a 96-well microtiter plate and then incubated at 37°C in an orbital shaker for 10 min. Protein concentrations were determined by an ELISA reader (Bio-Rad) at 595 nm. Distilled water was used as a blank sample, and a protein standard curve was obtained using bovine serum albumin as a protein standard.

**2.6. Determination of the Antibacterial Activity of BLIS.** The antibacterial activity of BLIS was determined using the agar well diffusion method. A total of 25 mL of Mueller–Hinton agar (Oxoid, UK) containing the test bacteria (1% v/v; *E. coli*, *S. Typhimurium*, *L. monocytogenes*, and *S. aureus*) at a density of  $1 \times 10^6 \text{ CFU} \cdot \text{mL}^{-1}$  was poured into the wells of a plate and allowed to solidify. A well (diameter, 6 mm) was made in the agar with a cork borer, and 100  $\mu\text{L}$  samples of BLIS were placed into the wells. After incubation at 37°C for 24 h, the diameter of the inhibition zone (mm) was measured. Distilled water and ampicillin 10  $\mu\text{g} \cdot \text{mL}^{-1}$  were used as controls. The antibacterial activity of BLIS was expressed as activity ( $A$ ) and specific activity ( $B$ ) [28]. Purification fold ( $C$ ) and yield activity (%) ( $D$ ) of the samples were also calculated.

BLIS activity ( $A$ ) was calculated as shown in equation (1) and expressed in units of  $\text{AU} \cdot \text{mL}^{-1}$ , where 1  $\text{AU} \cdot \text{mL}^{-1}$  was defined as the unit area of the inhibition zone per unit volume ( $\text{mm}^2 \cdot \text{mL}^{-1}$ ). In equation (1),  $L_z$  refers to the clear zone area ( $\text{mm}^2$ ),  $L_s$  refers to the well area ( $\text{mm}^2$ ), and  $V$  refers to the sample volume (mL).

$$A = \frac{L_z - L_s}{V}. \quad (1)$$

BLIS-specific activity ( $B$ ) was defined as the ratio of the total BLIS activity of the sample to the total protein concentration ( $\text{AU} \cdot \mu\text{g}^{-1}$ ) and calculated using equation (2), where  $A$  refers to the BLIS activity ( $\text{AU} \cdot \text{mL}^{-1}$ ),  $T_p$  refers to the total protein concentration ( $\mu\text{g}$ ) in the sample, and  $V$  refers to the sample volume (mL).

$$B = \frac{A \times V}{T_p \times V}. \quad (2)$$

Purification fold ( $C$ ) was defined as the ratio of the specific activity of the fraction obtained at each purification step ( $B_p$ ) to the specific activity of crude BLIS ( $B_0$ ) and calculated using equation (3), where  $B_p$  was the BLIS-specific activity of the fraction obtained at each steps of purification and  $B_0$  was

the BLIS-specific activity of crude BLIS.

$$C = \frac{B_p}{B_0}. \quad (3)$$

Yield activity ( $D$ ) was defined as the ratio of the total BLIS activity ( $\text{AU} \cdot \text{mL}^{-1}$ ) calculated at each step of purification to the total activity of crude BLIS and calculated using equation (4), where  $A$  was the BLIS activity ( $\text{AU} \cdot \text{mL}^{-1}$ ) in each step,  $V$  was the sample volume (mL), and  $A_0$  was the BLIS activity of crude BLIS.

$$D = \left( \frac{A \times V}{A_0} \right) \times 100. \quad (4)$$

**2.7. Analysis of Minimum Inhibitory and Bactericidal Concentrations.** Determination of the MIC of BLIS was conducted by preparing BLIS samples at several concentrations (i.e., 10, 5.0, 2.5, 1.25, 0.625, 0.312, 0.156, 0.078, 0.04, 0.02, 0.009, and 0.004  $\text{mg} \cdot \text{mL}^{-1}$ ). Each BLIS sample was placed on a microplate that had previously been inoculated with 0.1 mL of test bacteria (density,  $1 \times 10^6$ ) and 0.1 mL of MHB (HiMedia, India). The microplate was incubated for 24 h at 37°C. The growth of the test bacteria on the microplate was observed using a microplate reader (Bio-Rad) at 600 nm, and their viability was determined by the plate counting method [3]. The MIC was obtained from the lowest concentration of bacteriocin that could inhibit the growth of the test bacteria. The MBC of BLIS was evaluated as follows. After MIC determination, the liquid remaining on the microplate was inoculated with Mueller–Hinton agar (HiMedia) and then incubated for 24 h at 37°C. The MBC refers to the MIC of bacteriocin required to kill 99.9% of the tested bacteria.

**2.8. Determination of the Temperature and pH Stability of BLIS.** Evaluation of the temperature stability of BLIS was performed by dissolving all of the fractions in deionized water and then incubating the resulting solutions at 60, 80, or 100°C for 30 min or 121°C for 15 min. The solutions were cooled to room temperature and subjected to antibacterial activity tests [29]. The pH stability of BLIS was determined by adjusting the pH of the purified fractions to pH 2.0–10.0 by using 1  $\text{mol} \cdot \text{L}^{-1}$  HCl and 1  $\text{mol} \cdot \text{L}^{-1}$  NaOH as necessary and incubating for 2 h. Prior to the antibacterial activity test, the pH of the samples was set to pH 7.0. All antibacterial activity tests were performed by using the agar-well diffusion method, as described above.

**2.9. Analysis of Toxicity by Using Brine Shrimp Lethality Assay.** *Artemia salina* cysts were hatched in artificial seawater containing 27 g of NaCl in 3 L of distilled water and provided light and aeration. The larval hatching process was conducted for 48 h. Once hatched, the larval eggs were considered ready for analysis. The purified BLIS fraction showing the best specific activity was dissolved in artificial seawater to obtain test solutions with final BLIS concentrations of 2,000, 1,000, 200, and 20  $\mu\text{g} \cdot \text{mL}^{-1}$ . A total of 1 mL of each test solution was transferred to a separate test tube

and added with 10 two-day-old *A. salina* larvae by using a sterile syringe. The volume in the test tube was adjusted to 2 mL to achieve final BLIS concentrations of  $1 \text{ mg}\cdot\text{mL}^{-1}$ ,  $500 \text{ }\mu\text{g}\cdot\text{mL}^{-1}$ ,  $100 \text{ }\mu\text{g}\cdot\text{mL}^{-1}$ , and  $10 \text{ }\mu\text{g}\cdot\text{mL}^{-1}$ . The test tubes were incubated for 24 h, and the number of dead *A. salina* larvae was counted. The lethal concentration ( $\text{LC}_{50}$ ) of BLIS was determined via the probit analysis method with a 95% confidence interval using SPSS software. Each concentration was tested thrice, and artificial seawater was used as a negative control [30].

**2.10. LC-MS/MS Analysis and In Silico Study of the BLIS Fraction with the Greatest Activity.** The BLIS fraction with the greatest antibacterial activity was dissolved in 1 mL of water, centrifuged for 1 min, and then injected into a NanoLC Ultimate 3000 Tandem Q Exactive Plus Orbitrap HRMS instrument equipped with a Thermo PepMap RSLC C18 capillary column ( $75 \text{ }\mu\text{m} \times 15 \text{ cm}$ ,  $3 \text{ }\mu\text{m}$ ,  $100 \text{ \AA}$ ) and a Thermo Scientific™ 164649 trap column ( $30 \text{ }\mu\text{m}$ ,  $5 \text{ mm}$ ). The sample was eluted with  $\text{H}_2\text{O}$  with 0.1% formic acid (A) and acetonitrile with 0.1% formic acid (B) at a flow rate of  $300 \text{ nL}\cdot\text{min}^{-1}$ . The elution program was as follows: 2%–35% B for 30 min, 30%–90% B for 15 min, 90% B for 15 min, and 5% B for 30 min. Spectra were collected over the mass range of 200–2,000 m/z. The mass spectral results were analyzed using Proteome Discoverer 2.2 (Thermo Scientific), which uses the search engine SEQUEST HT, for database-based protein identification. The enzyme used was trypsin with a maximum miss cleavage of 2. The dynamic modifications applied were oxidation (for the amino acid methionine) and acetylation (for N-terminals). The percentages of hydrophobic and cationic amino acid residues were predicted using ProtParam (<https://web.expasy.org/protparam/>), and the physicochemical properties of the detected amino acid peptide sequences (i.e., sequence length, molecular weight (MW), hydrophobicity, and Boman index) were determined using PepDraw (<https://www.pepdraw.com/>).

**2.11. Statistical Analysis.** All experiments were performed as three independent replicates, and the results were expressed as mean  $\pm$  standard deviation. Data analysis was performed using SPSS 18.0 software. One-way analysis of variance (ANOVA) and Duncan's multiple range test (95% confidence interval) were applied to detect significant differences between means.

### 3. Results and Discussion

**3.1. Antibacterial Activity of Crude BLIS.** The neutralized CFS of six *Streptomyces* isolates showed potential inhibitory activity (Figure 1). The growth inhibition of *E. coli* and *S. aureus* was highest in the CFS of *S. globisporus* AIA12 and *S. misionensis* AIA17. Meanwhile, the lowest inhibition of growth of *E. coli* and *S. aureus* was found in CFS produced by *S. labedae* SCA-11 and *S. variabilis* AIA-10, respectively. ANOVA followed by Duncan's multiple range test indicated that the growth absorbance of test bacteria exposed to CFS was significantly lower than that of test bacteria not exposed




FIGURE 1: The growth absorbance (in 600 nm) of test bacteria in Mueller Hinton broth exposed to cell-free supernatant (CFS); white square: *E. coli*; light-gray square: *S. aureus*; C (-): control negative using Mueller Hinton broth inoculated with test bacteria without being exposed to CFS; C (+): control positive using ampicillin  $10 \text{ }\mu\text{g}\cdot\text{mL}^{-1}$ .

to CFS. This result indicates that the presence of extracellular metabolites produced by *Streptomyces* in CFS could inhibit the growth of the test bacteria and supports previous findings demonstrating the potential antibacterial properties of metabolites produced by *Streptomyces* isolated from the gut of *C. chanos* [23, 24]. The difference in antibacterial activity produced is due to differences in the concentration of extracellular metabolites produced [13]. Analysis of antibacterial activity using the agar well diffusion method confirmed these findings. Specifically, the concentrated CFS formed inhibition zones against all tested bacteria (Figure 2). These results show that crude BLIS has broad spectrum antibacterial activity.

The zones of inhibition determined in this study indicated that the six crude BLIS samples have better inhibitory activity against Gram-negative bacteria than against Gram-positive bacteria. This finding contradicts most studies reporting that bacteriocins are only active against Gram-positive bacteria [31, 32]. However, recent studies have reported the ability of several bacteriocins to inhibit Gram-negative bacteria. For instance, the bacteriocins synthesized by *Streptomyces nigrescens* inhibit *Vibrio parahaemolyticus*, bacteriocin SLG10 inhibits *E. coli*, and bacteriocin JLA-9 inhibits *E. coli*, *S. Typhimurium*, *Pseudomonas fluorescens*, and *Shigella flexneri* [3, 13, 33]. According to Pei et al. [3], the inhibitory activity of bacteriocins against Gram-negative bacteria is due to the ability of these substances to form interactions with nucleic acids and bacterial intracellular enzymes and damage the integrity of bacterial cell membranes. Choi and Lee [34] added that the inhibitory activity of bacteriocins against Gram-negative bacteria may also be due to their low MW. These bacteriocins can penetrate cell membranes through porins and directly attack the intracellular components of cells.

**3.2. Proteinaceous Nature Properties of Crude BLIS.** Since bacteriocins and BLIS are considered peptides, confirmation of the proteinaceous nature of these compounds is necessary. Analysis of the proteinaceous nature of the crude BLIS




FIGURE 2: Inhibition zone (mm) of concentrated cell-free supernatant (crude BLIS) against test bacteria determined using the agar well diffusion method; white square: *E. coli*; dark-gray square: *S. aureus*; light-gray square: *L. monocytogenes*; black square: *S. Typhimurium*; C (-): control negative using distilled water; C (+): control positive using ampicillin  $10 \mu\text{g}\cdot\text{mL}^{-1}$ .

revealed that the antimicrobial activity of the six extracts against *E. coli* was completely lost after treatment with proteinase-K and trypsin (Table 1). Moreover, whereas other crude BLIS fractions showed a significant decrease in activity, only the crude BLIS of *S. variabilis* SCA-11 and SCA-5 completely lost their activity following pepsin treatment. These findings are consistent with those of Lasik-Kurdyś and Sip [35], who reported that BLIS produced by *Oenococcus oeni* loses its activity after exposure to pronase E, proteinase-K, trypsin, pepsin, and  $\alpha$ -chymotrypsin. Moračanin et al. [36] also found that the bacteriocin produced by *Leuconostoc mesenteroides* loses its antilisteria activity after exposure to pepsin, papain, and proteinase-K. These results confirm the proteinaceous nature of active metabolites in crude BLIS, which may be responsible for the latter's antibacterial activity.

**3.3. Stability of Crude BLIS.** Knowledge of the temperature and pH stability of BLIS is important because good stability is necessary to realize its applications in food processing. Among the crude samples assayed in this work, the crude BLIS of *S. variabilis* SCA-5 and *S. labedae* SCA-8 were the most stable (Figure 3). Both extracts could maintain over 50% of their antibacterial activity after heating up to  $100^\circ\text{C}$ . Even in crude BLIS of *S. variabilis* SCA-5, the activity was maintained up to  $121^\circ\text{C}$ . Besides, both extracts were also able to maintain their antibacterial activity at exposure to a wide range of pH 2.0–7.0. However, significant decreases in activity occurred when the temperature and pH were increased beyond these ranges. This finding is consistent with the results of Hernández-Saldaña et al. [13], who reported that the bacteriocin produced by *S. griseus* and *S. nigrescens* shows activity loss of up to 50% at  $100^\circ\text{C}$  and stable at pH 3–7. Meanwhile, in *S. violaceoruber* and *S. bottropensis*, the activity decreased up to 70% at the same temperature. Du et al. [31] reported that plantaricin GZ1-27 maintains its activity at temperatures of up to  $80^\circ\text{C}$  for 30 min and is stable at pH 2.0–6.0.

**3.4. Antibacterial Activity of BLIS Ultrafiltered Fractions.** Antibacterial activity analysis using the agar well diffusion method showed that the BLIS ultrafiltered (BLIS-UF) frac-

tion with MW > 10 kDa could produce the largest inhibition zone (Figure 4). This trend is similar to the trend of BLIS activity observed. However, BLIS-specific activity calculations indicated that this fraction has the lowest activity among the fractions obtained. BLIS-specific activity describes the ratio of BLIS activity to the total protein concentration, where this value is the activity per one  $\mu\text{g}$  of protein contained in the fraction. The greater the BLIS-specific activity of a fraction, the more active it is [28]. Compared with the BLIS-UF fraction with MW > 10 kDa, those with MW < 3 kDa and 3–10 kDa had higher BLIS-specific activity. These results indicate that the active fraction of BLIS *Streptomyces* has a low MW, consistent with previous studies reporting that BLIS produced by *Streptomyces* have MW < 3 kDa, such as *Streptomyces griseus* IFO 1330 (1,833 kDa), *Streptomyces griseus* XylebKG-1 ADFC02 (~2 kDa), and *Streptomyces nigrescens* ATCC 23941 (3 kDa). BLIS shows inhibitory activity against *Bacillus cereus*, *Vibrio parahaemolyticus*, *Enterococcus casseliflavus*, *L. monocytogenes*, and *Micrococcus luteus* [13, 16].

Among the fractions obtained, BLIS-UF SCA-8 with MW < 3 kDa showed the highest BLIS-specific activity. This fraction revealed broad spectrum antibacterial effects against *E. coli*, *S. aureus*, *L. monocytogenes*, and *S. Typhimurium* with specific activities of 635.6, 167.9, 664.5, and  $615.5 \text{ AU}\cdot\mu\text{g}^{-1}$ , respectively (Table 2). These results reflect an increase in BLIS-specific activity of up to  $396.9 \text{ AU}\cdot\mu\text{g}^{-1}$  compared with that of crude BLIS. Such results may be attributed to the purification level of crude BLIS, which was increased by up to 2.5 times. Application of ultrafiltration membranes appeared to be quite effective in separating crude BLIS into purified fractions based on MW. Yield recoveries ranged from 15.7% to 99.6%. Among the fractions obtained, that with MW < 3 kDa revealed the lowest yield. The results of the present study are similar to those of Zacharof et al. [37], who found a decrease in yield recovery from 68% to 36% after filtration using 1 kDa MWCO nanofilters.

#### 4. MIC and MBC of BLIS Ultrafiltration SCA-8 with MW < 3 kDa Fraction

The MIC and MBC of BLIS-UF SCA-8 with MW < 3 kDa are shown in Table 3. This fraction revealed MICs ranging

TABLE 1: Inhibitory zone (mm) of crude BLIS after proteolytic enzyme treatment against *Escherichia coli*.

Treatment	Inhibition zone (mm)					
	SCA-5	SCA-8	SCA-11	AIA-10	AIA-12	AIA-17
Proteinase-K	0	0	0	0	0	0
Pepsin	0	7.0 ± 0.32	0	7.3 ± 0.03	6.4 ± 0.07	7.4 ± 0.10
Trypsin	0	0	0	0	0	0
Untreated control	19.2 ± 0.10	16.5 ± 0.13	24.1 ± 0.12	22.6 ± 0.05	21.7 ± 0.18	20.4 ± 0.19



FIGURE 3: Inhibitory zone (mm) of crude BLIS after heat (a) and pH (b) treatment against *E. coli*; ■: SCA-5; ●: SCA-8; ◇: SCA-11; ▲: AIA-10; ○: AIA-12; ◆: AIA-17.FIGURE 4: Inhibition zone (mm) of BLIS ultrafiltration fraction based on molecular weight (<3 kDa, 3–10 kDa, and >10 kDa) against *E. coli* (a), *S. aureus* (b), *L. monocytogenes* (c), and *S. Typhimurium* (d) using the agar well diffusion method; light-gray square: >10 kDa; dark-gray square: 3–10 kDa; white square: <3 kDa.



TABLE 3: The MIC and MBC of BLIS-UF SCA-8 with molecular weight less than 3 kDa.

Bacterial test	MIC (mg·mL <sup>-1</sup> )	MBC (mg·mL <sup>-1</sup> )
<i>Escherichia coli</i> ATCC 25922	0.31	0.62
<i>Salmonella</i> Typhimurium ATCC 14028	0.62	1.25
<i>Staphylococcus aureus</i> ATCC 25923	0.04	0.08
<i>Listeria monocytogenes</i> ATCC 35152	0.04	0.16

TABLE 4: SCA-8 with MW < 3 kDa against *Escherichia coli*.

Stability test	Inhibition zone (mm)	Residue activity (%)*
<i>Heat</i>		
60°C	23.78 ± 0.25	97.13
80°C	23.50 ± 0.07	95.63
100°C	18.90 ± 0.49	70.49
121°C	12.23 ± 0.32	34.02
<i>pH</i>		
2	22.80 ± 0.21	91.80
4	22.00 ± 0.28	87.43
6	23.53 ± 0.11	95.77
7	21.85 ± 0.42	86.61
8	14.83 ± 0.25	48.22
10	0	0
<i>Enzyme</i>		
Proteinase-K	0	0
Pepsin	6.35 ± 0.14	1.93
Trypsin	0	0
<i>Untreated control</i>	24.3 ± 0.14	100

TABLE 5: LC<sub>50</sub> by the brine shrimp lethality test of most potential BLIS SCA-8 with MW < 3 kDa fraction.

Sample	Concentration (μg·mL <sup>-1</sup> )	Mortality (%)	LC <sub>50</sub> (μg·mL <sup>-1</sup> )
BLIS SCA-8 with MW < 3	1000	96.6	226.975
	500	66.6	
	100	40	
	10	13.3	

from 0.04 mg·mL<sup>-1</sup> to 0.62 mg·mL<sup>-1</sup> and MBCs ranging from 0.08 mg·mL<sup>-1</sup> to 1.25 mg·mL<sup>-1</sup>. The lowest MIC of this fraction (0.04 mg·mL<sup>-1</sup>) was obtained in *S. aureus* and *L. monocytogenes*, and its lowest MBC (0.08 mg·mL<sup>-1</sup>) was observed in *S. aureus*. The MIC and MBC obtained in this study are higher than those of the bacteriocins SLG10 and JLA-9. The bacteriocin SLG10 produced by *Lactobacillus plantarum* shows MICs in the range of 0.016–0.032 mg·mL<sup>-1</sup> and MBCs in the range of 0.016–0.064 mg·mL<sup>-1</sup> and is most

lethal to *L. monocytogenes* CICC 21529 [3]. Bacteriocin JLA-9 has MBCs in the range of 0.016–0.032 mg·mL<sup>-1</sup> [33]. Differences in MICs and MBCs obtained in this study relative to those in previous reports may be related to the purity of the bacteriocins. Specifically, bacteriocins SLG10 and JLA-9 were tested in their pure form, whereas BLIS-UF SCA-8 with MW < 3 kDa is only semipurified at best. Sharma et al. [38] indicated that further purification may reduce MIC, which has implications for smaller MIC doses in certain microorganisms.

4.1. *Stability of BLIS Ultrafiltration SCA-8 with MW < 3 kDa Fraction.* Among the fractions obtained, BLIS-UF SCA-8 with MW < 3 kDa revealed the greatest BLIS-specific activity. Stability analysis of this fraction showed better stability at high temperatures and pH, as well as improved sensitivity to enzymes, compared with crude BLIS. BLIS-UF SCA-8 with MW < 3 kDa retained over 70% of its antibacterial activity despite exposure to temperatures of 60–100°C for 30 min and solution pH of 2.0–7.0. It also showed enhanced sensitivity to pepsin (Table 4). Considering that food materials comprise various matrices and are subjected to various processing methods, such as heating or acidification [39, 40], the excellent stability of BLIS-UF SCA-8 with MW < 3 kDa reveals its promising potential use as a food biopreservative.

$$* \text{Residue activity} = \frac{\text{inhibition zone of threatened sample} - 6}{\text{inhibition zone of unthreatened control} - 6} \times 100. \quad (5)$$

4.2. *Median Lethal Concentration of BLIS Ultrafiltration SCA-8 with MW < 3 kDa Fraction.* The most promising BLIS fraction, BLIS-UF SCA-8 with MW < 3 kDa, was subjected to the brine shrimp lethality assay to determine its LC<sub>50</sub> [41]. The test results showed that the mortality rate of *A. salina* increased with increasing BLIS concentration, in which a probit test showed that this fraction has LC<sub>50</sub> of 226.975 μg·mL<sup>-1</sup> (moderate toxicity) (Table 5). Hamidi et al. [42] classified toxicity based on LC<sub>50</sub> as follows: highly toxic, 0–100 μg·mL<sup>-1</sup>; moderately toxic, 100–500 μg·mL<sup>-1</sup>; weakly toxic, 500–1,000 μg·mL<sup>-1</sup>; and nontoxic, >1,000 μg·mL<sup>-1</sup>. The LC<sub>50</sub> of BLIS-UF SCA-8 with MW < 3 kDa was higher than that of the purified bacteriocin from *Lactobacillus lactis*, which revealed an LC<sub>50</sub> of 21.54 μg·mL<sup>-1</sup> [43]. The difference in LC<sub>50</sub> between BLIS samples may be attributed to differences in the purity of the samples.

LC<sub>50</sub> in *A. salina* and LD<sub>50</sub> in animal models has a positive correlation, in which LC<sub>50</sub> < 10 μg·mL<sup>-1</sup> has an LD<sub>50</sub> of 100–1,000 mg·kg<sup>-1</sup>, LC<sub>50</sub> < 20 μg·mL<sup>-1</sup> has an LD<sub>50</sub> of 1,000–2,500 mg·kg<sup>-1</sup>, and LC<sub>50</sub> > 25 μg·mL<sup>-1</sup> has an LD<sub>50</sub> of 2,500–8,000 mg·kg<sup>-1</sup> [44]. On the basis of these studies, BLIS-UF SCA-8 with MW < 3 kDa may be assumed to have an LD<sub>50</sub> of over 2500 mg·kg<sup>-1</sup> (weakly toxic) because its LC<sub>50</sub> to *A. salina* is 226.975 μg·mL<sup>-1</sup>. Erhirhie et al. [45] classified LD<sub>50</sub> according to the dose range as follows: extremely toxic, <5 mg·kg<sup>-1</sup>; highly toxic, 5–50 mg·kg<sup>-1</sup>; moderately toxic, 50–500 mg·kg<sup>-1</sup>; weakly toxic, 500–5,000 mg·kg<sup>-1</sup>; nontoxic, 5000–15,000 mg·kg<sup>-1</sup>, and relatively harmless, >15,000 mg·kg<sup>-1</sup>. These findings demonstrate that BLIS-UF






FIGURE 5: LC-MS/MS chromatogram profile of BLIS UF-SCA-8 with MW < 3 kDa fraction.

TABLE 6: Identified peptide sequences (relative abundance > 60%) by Proteome Discoverer 2.2 (Thermo Scientific) in BLIS-UF SCA-8 with MW < 3 kDa fraction.

RT (min)	Relative abundance (%)	Accession	Sequence	Molecular weight (Da)	Number of amino acid	Hydrophobicity (kcal·mol <sup>-1</sup> )	Boman index
16.11	61.67	F2IY40	TAVTEWTVAHAGGER	1584.77	15	20.84	1.56
16.52	61.37	A0A2A4MKN2	VTMNKEIDGLER	1420.71	12	22.16	1.16
16.77	69.94	A0A087LGR3	EQLSAFLQSEEGK	1465.71	13	21.49	2.9
16.91	82	A0A1C9VDC5	SAGPMERIFASGMR	1345.66	14	15.34	2.17
16.93	86.02	K2NT65	AGGAYVPIDPGYPSEK	1493.69	16	19.31	1.81
17.08	98.53	A0A087LFG0	EVGASSKADMGK	1195.56	12	23.86	1.92
17.46	100	A0A2G7E6K9	TAAGLEAGETVR	1174.60	12	19.56	1.17
18.07	77.3	A0A217EF20	QAAPYPLPADPDAR	1481.73	14	18.36	1.795
18.8	98.53	A0A1U9ZU28	AFDPPPTTHPPATDAR	1690.81	16	20.56	1.45
19.44	71.08	A0A397RL80	DLGAWPALPGEDTSTSSSGPTAAPSISAHQ	2908.35	30	26.22	1.84
19.98	80.64	A0A1B1AP88	RDAPGASPGGTAGRGGPR	1636.82	18	26.5	2.27

Accession: the master protein accession as found in the database (UniProt).

SCA-8 with MW < 3 kDa may be developed as a promising preservative agent.

4.3. Identification of the Peptide Sequence of the BLIS Ultrafiltration SCA-8 with MW < 3 kDa Fraction. Peptide identification by LC-MS/MS can provide information on the molecular mass of the amino acid sequence of the peptide constituents of a sample [42]. LC-MS/MS of BLIS-UF SCA-8 with MW < 3 kDa followed by database-based protein analysis using Proteome Discoverer 2.2 succeeded in identifying 130 proteins (retention times of 15.21–19.98 min) (Figure 5; Table 6). Eleven peptides with over 60% relative abundance and MW ranging from 1.34 kDa to 2.90 kDa appeared to be responsible for the antibacterial activity of this fraction (Table 6). *In silico* analysis of physicochemical properties using ProtParam (<https://web.expasy.org/protparam/>) and PepDraw (<http://www.tulane.edu/~biochem/WW/PepDraw/>) revealed that each peptide having hydrophobic amino acids ranging from 38.5 to 75%, and high hydrophobicity (15.34–26.5 kcal·mol<sup>-1</sup>) (Table 6). Gadde et al. [46] found that antimicrobial peptides are generally hydrophobic and cationic. Cationic properties may help promote interactions between peptides and bacte-

rial cell membranes or walls [47]. Hydrophobic properties could destroy cell walls or membranes by forming pores, resulting in cell lysis [48]. Protein-binding identification (Boman index) was conducted using an APD-based prediction program (<http://aps.unmc.edu/AP/main.php>). The detected proteins revealed high protein binding potential, especially those detected at 16.77 min (Table 6). Boman [49] stated that if a peptide or protein has a positive Boman index and is over 2.48 kcal·mol<sup>-1</sup>, the protein or peptide is highly likely to be able to bind to bacterial cell membranes.

Bacteriocins may be divided into three classes. Class I includes bacteriocins with posttranslational modified amino acid, which heat stable, have a low MW (<5 kDa), and are only able to inhibit Gram-positive bacteria. Class II includes bacteriocins with low MW (<10 kDa), heat stable, which do not contain a posttranslational modified amino acid and can inhibit both Gram-positive and negative bacteria. Finally, class III includes bacteriocins with large MW (>30 kDa) and is generally heat labile [50]. According to this classification and the data obtained in the present study, BLIS-UF SCA-8 with MW < 3 kDa may be a class II bacteriocin. This assumption is based on the MW of BLIS-UF SCA-8 (<3 kDa), its heat stable characteristics, its ability to inhibit

Gram-positive and negative bacteria, and the absence of a posttranslational modified amino acid in its peptide sequence.

## 5. Conclusions

*Streptomyces* is a promising producer of bioactive metabolites. The present study showed that six isolates of *Streptomyces* isolated from the gut of *C. chanos* could produce BLIS. The proteinaceous properties of BLIS were confirmed with assays involving several proteolytic enzymes. Crude BLIS showed broad spectrum antibacterial activity and high temperature and pH stability. Fractionation with ultrafiltration membranes revealed that BLIS fractions with MWs of <3 kDa and 3–10 kDa present the greatest activity. Calculation of the specific activities of these fractions demonstrated that BLIS-UF SCA-8 with MW < 3 kDa was more active than the fraction with MW of 3–10 kDa. BLIS-UF SCA-8 with MW < 3 kDa showed an increase in purity of up to 2.5 times, good pH and heat stability, and moderate toxicity to *A. salina*. Identification of the peptide sequence of this fraction through LC-MS/MS revealed that the peptides of this fraction are mostly composed of hydrophobic amino acids with low MW. Overall, the results of this study demonstrate the promising potential of BLIS *Streptomyces* as a candidate antibacterial agent for food applications.

## Data Availability

All datasets generated or analyzed during this study are available upon reasonable request from the corresponding author.

## Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

## Acknowledgments

We acknowledge the Ministry of Research, Technology and Higher Education of the Republic of Indonesia for its funding research under contract no. 2680/IT3.L1/PN/2020.

## References

- [1] H. Ahn, J. Kim, and W. J. Kim, "Isolation and characterization of bacteriocin-producing *Pediococcus acidilactici* HW01 from malt and its potential to control beer spoilage lactic acid bacteria," *Food Control*, vol. 80, pp. 59–66, 2017.
- [2] S. B. Wayah and K. Philip, "Characterization, yield optimization, scale up and biopreservative potential of fermencin SA715, a novel bacteriocin from *Lactobacillus fermentum* GA715 of goat milk origin," *Microbial Cell Factories*, vol. 17, no. 1, pp. 1–18, 2018.
- [3] J. Pei, W. Jin, A. M. Abd El-Aty et al., "Isolation, purification, and structural identification of a new bacteriocin made by *Lactobacillus plantarum* found in conventional kombucha," *Food Control*, vol. 110, pp. 106923–106928, 2020.
- [4] L. Siroli, F. Patrignani, D. I. Serrazanetti, F. Gardini, and R. Lanciotti, "Innovative strategies based on the use of bio-control agents to improve the safety, shelf-life and quality of minimally processed fruits and vegetables," *Trends in Food Science and Technology*, vol. 46, no. 2, pp. 302–310, 2015.
- [5] B. Ramos, F. A. Miller, T. R. S. Brandão, P. Teixeira, and C. L. M. Silva, "Fresh fruits and vegetables—an overview on applied methodologies to improve its quality and safety," *Innovative Food Science and Emerging Technologies*, vol. 20, pp. 1–15, 2013.
- [6] V. L. Cavera, T. D. Arthur, D. Kashtanov, and M. L. Chikindas, "Bacteriocins and their position in the next wave of conventional antibiotics," *International Journal of Antimicrobial Agents*, vol. 46, no. 5, pp. 494–501, 2015.
- [7] N. L. Md Sidek, M. Halim, J. S. Tan, S. Abbasiliasi, S. Mustafa, and A. B. Ariff, "Stability of bacteriocin-like inhibitory substance (BLIS) produced by *Pediococcus acidilactici* KP10 at different extreme conditions," *BioMed Research International*, vol. 2018, Article ID 5973484, 11 pages, 2018.
- [8] I. Sugrue, P. M. O'Connor, C. Hill, C. Stanton, and R. P. Ross, "Actinomyces Produces defensin-like bacteriocins (actifensins) with a highly degenerate structure and broad antimicrobial activity," *Journal of Bacteriology*, vol. 202, no. 4, pp. 1–15, 2020.
- [9] J. Minnaard and A. M. Alippi, "Partial characterization of bacteriocin-like compounds from two strains of *Bacillus cereus* with biological activity against *Paenibacillus larvae*, the causal agent of American foulbrood disease," *Letters in Applied Microbiology*, vol. 63, no. 6, pp. 442–449, 2016.
- [10] M. Zimina, O. Babich, A. Prosekov et al., "Overview of global trends in classification, methods of preparation and application of bacteriocins," *Antibiotics*, vol. 9, no. 9, p. 553, 2020.
- [11] K. B. Lim, M. P. Balolong, S. H. Kim, J. K. Oh, J. Y. Lee, and D. K. Kang, "Isolation and characterization of a broad spectrum bacteriocin from *Bacillus amyloliquefaciens* RX7," *BioMed Research International*, vol. 2016, Article ID 8521476, 7 pages, 2016.
- [12] S. Soltani, R. Hammami, P. D. Cotter et al., "Bacteriocins as a new generation of antimicrobials: toxicity aspects and regulations," *FEMS Microbiology Reviews*, vol. 45, no. 1, pp. 1–24, 2021.
- [13] O. F. Hernández-Saldaña, J. E. Barboza-Corona, D. K. Bideshi, and L. E. Casados-Vázquez, "New bacteriocin-like substances produced by *Streptomyces* species with activity against pathogens," *Folia Microbiologica (Praha)*, vol. 65, no. 4, pp. 669–678, 2020.
- [14] L. H. Lee, N. Zainal, A. S. Azman et al., "*Streptomyces pluripotens* sp. nov., a bacteriocin-producing *Streptomyces* that inhibits methicillin-resistant *Staphylococcus aureus*," *International Journal of Systematic and Evolutionary Microbiology*, vol. 64, Part\_9, pp. 3297–3306, 2014.
- [15] M. H. Farris, C. Duffy, R. H. Findlay, and J. B. Olson, "*Streptomyces scopuliridis* sp. nov., a bacteriocin-producing soil *Streptomyces*," *International Journal of Systematic and Evolutionary Microbiology*, vol. 61, no. 9, pp. 2112–2116, 2011.
- [16] J. Claesen and M. J. Bibb, "Biosynthesis and regulation of griseumycin, a new member of the linaridin family of ribosomally synthesized peptides produced by *Streptomyces griseus* IFO 13350," *Journal of Bacteriology*, vol. 193, no. 10, pp. 2510–2516, 2011.
- [17] L. Huo, S. Rachid, M. Stadler, S. C. Wenzel, and R. Müller, "Synthetic biotechnology to study and engineer ribosomal

- bottomycin biosynthesis," *Chemistry & Biology*, vol. 19, no. 10, pp. 1278–1287, 2012.
- [18] P. Sivalingam, K. Hong, J. Pote, and K. Prabakar, "Extreme environment streptomycetes: potential sources for new antibacterial and anticancer drug leads?," *Journal of Microbiology*, vol. 2019, article 5283948, 20 pages, 2019.
- [19] G. R. Lewin, C. Carlos, M. G. Chevrette et al., "Evolution and ecology of Actinobacteria and their bioenergy applications," *Annual Review of Microbiology*, vol. 70, no. 1, pp. 235–254, 2017.
- [20] L. M. Sanchez, W. R. Wong, R. M. Riener, C. J. Schulze, and R. G. Lington, "Examining the fish microbiome: vertebrate-derived bacteria as an environmental niche for the discovery of unique marine natural products," *PLoS One*, vol. 7, no. 5, article e35398, 2012.
- [21] S. Tan, G. Moore, and J. Nodwell, "Put a bow on it: knotted antibiotics take center stage," *Antibiotics*, vol. 8, no. 3, pp. 117–117, 2019.
- [22] M. Jami, M. Ghanbari, W. Kneifel, and K. J. Domig, "Phylogenetic diversity and biological activity of culturable Actinobacteria isolated from freshwater fish gut microbiota," *Microbiological Research*, vol. 175, pp. 6–15, 2015.
- [23] M. A. Kurnianto, H. D. Kusumaningrum, and H. N. Lioe, "Characterization of Streptomyces isolates associated with estuarine fish *Chanos chanos* and profiling of their antibacterial metabolites-crude-extract," *Journal of Microbiology*, vol. 2020, article 8851947, 12 pages, 2020.
- [24] M. A. Kurnianto, H. D. Kusumaningrum, H. N. Lioe, and E. Chasanah, "Antibacterial and antioxidant potential of ethyl acetate extract from *Streptomyces* AIA12 and AIA17 isolated from gut of *Chanos chanos*," *Biodiversitas*, vol. 22, no. 8, pp. 3196–3206, 2021.
- [25] M. Memarpoor-Yazdi, A. Asoodeh, and J. K. Chamani, "A novel antioxidant and antimicrobial peptide from hen egg white lysozyme hydrolysates," *Journal of Functional Foods*, vol. 4, no. 1, pp. 278–286, 2012.
- [26] S. N. Andayani, H. N. Lioe, C. H. Wijaya, and M. Ogawa, "Umami fractions obtained from water-soluble extracts of red oncom and black oncom—Indonesian fermented soybean and peanut products," *Journal of Food Science*, vol. 85, no. 3, pp. 657–665, 2020.
- [27] N. Jamaluddin, A. B. Ariff, and F. W. F. Wong, "Purification of a bacteriocin-like inhibitory substance derived from *Pediococcus acidilactici* Kp10 by an aqueous micellar two-phase system," *Biotechnology Progress*, vol. 35, no. 1, p. e2719, 2019.
- [28] F. Feliatra, Z. A. Muchlisin, H. Y. Teruna, W. R. Utamy, N. Nursyirwani, and A. Dahliaty, "Potential of bacteriocins produced by probiotic bacteria isolated from tiger shrimp and prawns as antibacterial to *Vibrio*, *Pseudomonas*, and *Aeromonas* species on fish," *F1000Research*, vol. 7, pp. 1–19, 2018.
- [29] E. L. Leite, A. F. D. Oliveira Jr., F. L. R. D. Carmo et al., "Bacteriocins as an alternative in the treatment of infections by *Staphylococcus aureus*," *Anais da Academia Brasileira de Ciências*, vol. 92, article e20201216, Supplement 2, 2020.
- [30] S. Rahayu, L. Fitri, and Y. S. Ismail, "Short communication: endophytic actinobacteria isolated from ginger (*Zingiber officinale*) and its potential as a pancreatic lipase inhibitor and its toxicity," *Biodiversitas*, vol. 20, no. 5, pp. 1312–1317, 2019.
- [31] H. Du, J. Yang, Z. Lu et al., "Purification, characterization, and mode of action of plantaricin GZ1-27, a novel bacteriocin against *Bacillus cereus*," *Journal of Agricultural and Food Chemistry*, vol. 66, no. 18, pp. 4716–4724, 2018.
- [32] C.-B. Liu, B. Shan, H.-M. Bai, J. Tang, L.-Z. Yan, and Y.-B. Ma, "Hydrophilic/hydrophobic characters of antimicrobial peptides derived from animals and their effects on multidrug resistant clinical isolates," *Dongwuxue Yanjiu*, vol. 36, no. 1, pp. 41–47, 2015.
- [33] S. Zhao, J. Han, X. Bie, Z. Lu, C. Zhang, and F. Lv, "Purification and characterization of plantaricin JLA-9: a novel bacteriocin against *Bacillus* spp. produced by *Lactobacillus plantarum* JLA-9 from Suan-Tsai, a traditional Chinese fermented cabbage," *Journal of Agricultural and Food Chemistry*, vol. 64, no. 13, pp. 2754–2764, 2016.
- [34] U. Choi and C. R. Lee, "Antimicrobial agents that inhibit the outer membrane assembly machines of gram-negative bacteria," *Journal of Microbiology and Biotechnology*, vol. 29, no. 1, pp. 1–10, 2019.
- [35] M. Lasik-Kurdyś and A. Sip, "Evaluation of the antimicrobial activity of bacteriocin-like inhibitory substances of enological importance produced by *Oenococcus oeni* isolated from wine," *European Food Research and Technology*, vol. 245, no. 2, pp. 375–382, 2019.
- [36] S. V. Moračanin, L. Turubatović, M. Škrinjar, and D. Obradović, "Antilisterial activity of bacteriocin isolated from *Leuconostoc mesenteroides* ssp. *mesenteroides* IMAU:10231 in the production of sremska sausages: lactic acid bacteria isolation, bacteriocin identification and meat application experiments," *Food Technology and Biotechnology*, vol. 51, no. 2, pp. 247–256, 2013.
- [37] M. P. Zacharof, G. M. Coss, S. J. Mandale, and R. W. Lovitt, "Separation of *Lactobacilli* bacteriocins from fermented broths using membranes," *Process Biochemistry*, vol. 48, no. 8, pp. 1252–1261, 2013.
- [38] G. Sharma, S. Dang, S. Gupta, and R. Gabrani, "Antibacterial activity, cytotoxicity, and the mechanism of action of bacteriocin from *Bacillus subtilis* GAS101," *Medical Principles and Practice*, vol. 27, no. 2, pp. 186–192, 2018.
- [39] J. An, W. Zhu, Y. Liu et al., "Purification and characterization of a novel bacteriocin CAMT2 produced by *Bacillus amyloliquefaciens* isolated from marine fish *Epinephelus areolatus*," *Food Control*, vol. 51, pp. 278–282, 2015.
- [40] J. A. Leite, F. L. Tulini, F. B. Reis-Teixeira et al., "Bacteriocin-like inhibitory substances (BLIS) produced by *Bacillus cereus*: preliminary characterization and application of partially purified extract containing BLIS for inhibiting *Listeria monocytogenes* in pineapple pulp," *Lebensmittel-Wissenschaft & Technologie*, vol. 72, pp. 261–266, 2016.
- [41] J. L. Carballo, Z. L. Hernández-Inda, P. Pérez, and M. D. García-Grávalos, "A comparison between two brine shrimp assays to detect in vitro cytotoxicity in marine natural products," *BMC Biotechnology*, vol. 2, no. 1, p. 17, 2002.
- [42] R. M. Hamidi, B. Jovanova, and T. Kadifkova Panovska, "Toxicological evaluation of the plant products using brine shrimp (*Artemia salina* L.) model. Maced," *Pharmaceutical Bulletin*, vol. 60, no. 1, pp. 9–18, 2014.
- [43] G. Rajaram, P. Manivsagan, U. Gunasekaran et al., "Isolation, identification and characterization of bacteriocin from *Lactobacillus lactis* and its antimicrobial and cytotoxic properties," *African Journal of Pharmacy and Pharmacology*, vol. 4, no. 12, pp. 895–902, 2010.
- [44] A. Logarto Parra, R. Silva Yhebra, I. Guerra Sardiñas, and L. Iglesias Buela, "Comparative study of the assay of *Artemia salina* L. and the estimate of the medium lethal dose (LD50

- value) in mice, to determine oral acute toxicity of plant extracts," *Phytomedicine*, vol. 8, no. 5, pp. 395–400, 2001.
- [45] E. O. Erhirhie, C. P. Ihekwereme, and E. E. Ilodigwe, "Advances in acute toxicity testing: strengths, weaknesses and regulatory acceptance," *Interdisciplinary Toxicology*, vol. 11, no. 1, pp. 5–12, 2018.
- [46] U. Gadde, W. H. Kim, S. T. Oh, and H. S. Lillehoj, "Alternatives to antibiotics for maximizing growth performance and feed efficiency in poultry: a review," *Animal Health Research Reviews*, vol. 18, no. 1, pp. 26–45, 2017.
- [47] J. Strauss, A. Kadilak, C. Cronin, C. M. Mello, and T. A. Camezano, "Binding, inactivation, and adhesion forces between antimicrobial peptide cecropin P1 and pathogenic *E. coli*," *Colloids Surfaces B Biointerface*, vol. 75, no. 1, pp. 156–164, 2010.
- [48] Z. Tang, L. Xu, B. Shi et al., "Oral administration of synthetic porcine beta-defensin-2 improves growth performance and cecal microbial flora and down-regulates the expression of intestinal Toll-like receptor-4 and inflammatory cytokines in weaned piglets challenged with enterotoxigenic *Escherichia coli*," *Animal Science Journal*, vol. 87, no. 10, pp. 1258–1266, 2016.
- [49] H. G. Boman, "Antibacterial peptides: basic facts and emerging concepts," *Journal of Internal Medicine*, vol. 254, no. 3, pp. 197–215, 2003.
- [50] R. Kumariya, A. K. Garsa, Y. S. Rajput, S. K. Sood, N. Akhtar, and S. Patel, "Bacteriocins: classification, synthesis, mechanism of action and resistance development in food spoilage causing bacteria," *Microbial Pathogenesis*, vol. 128, pp. 171–177, 2019.